The FDA expanded approval for Ionis Pharmaceuticals’ Tryngolza (olezarsen), allowing use in adults with severe hypertriglyceridemia and building on encouraging phase 3 results released last September. The update carries priority review and breakthrough therapy designations, which Ionis says reflect the strength of the clinical package. The broader label increases Tryngolza’s addressable market by moving beyond the narrower patient definitions that previously limited uptake. The decision also supports Ionis’ broader strategy to expand beyond early launches by pairing regulatory milestones with data-driven indication growth. For clinicians, the expansion may add another option for patients who require rapid triglyceride reduction and face limited alternatives. For payers and hospitals, the label broadening may change treatment pathways and testing demand tied to eligibility criteria.